Kiora Pharmaceuticals Inc
KPRX
Company Profile
Business description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Contact
332 Encinitas Boulevard
Suite 102
EncinitasCA92024
USAT: +1 858 224-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,180.20 | 43.00 | -0.47% |
| CAC 40 | 8,274.57 | 53.29 | -0.64% |
| DAX 40 | 24,066.70 | 22.48 | 0.09% |
| Dow JONES (US) | 48,463.72 | 72.27 | -0.15% |
| FTSE 100 | 10,559.58 | 49.48 | -0.47% |
| HKSE | 26,255.15 | 307.83 | 1.19% |
| NASDAQ | 24,016.02 | 376.94 | 1.59% |
| Nikkei 225 | 59,549.59 | 1,415.35 | 2.43% |
| NZX 50 Index | 13,095.24 | 18.66 | 0.14% |
| S&P 500 | 7,022.95 | 55.57 | 0.80% |
| S&P/ASX 200 | 8,963.70 | 53.50 | -0.59% |
| SSE Composite Index | 4,048.63 | 21.43 | 0.53% |